RVTY earnings analysis
What we found in RVTY's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Revvity delivered Q2 revenue of $729.688 million and adjusted EPS of $1.41, up approximately 1.3% and 207% year over year, respectively, and both exceeded consensus estimates. Diagnostics growth and the raised full-year outlook of $2.83-$2.86 billion in revenue and $5.30-$5.40 adjusted EPS support a bullish trend, although Life Sciences declined organically and the China divestiture introduces execution risk. The filing extract does not include the income-statement detail needed to calculate current gross margin, operating margin, or free cash flow.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew year over year and sequentially
- Q2 revenue was $729.688 million, up from $720 million in Q2 2025 and $711 million in Q1 2026, representing approximately 1.3% year-over-year and 2.6% sequential growth.
- Adjusted EPS materially exceeded prior periods
- Adjusted EPS was $1.41 versus $0.46 in Q2 2025 and $0.36 in Q1 2026, increases of approximately 207% year over year and 292% sequentially.
- Q2 results beat consensus
- Q2 adjusted EPS of $1.41 exceeded the $1.22 consensus estimate by $0.19, while revenue of $729.688 million exceeded the $703.597 million estimate by $26.091 million.
- Diagnostics led segment performance
- Diagnostics delivered 11% organic growth, providing the principal reported segment growth driver; Life Sciences organic revenue declined, indicating an uneven recovery across the portfolio.
- Full-year outlook was raised
- Management raised full-year pro forma revenue guidance to $2.83-$2.86 billion from $2.81-$2.84 billion and adjusted EPS guidance to $5.30-$5.40 from $5.20-$5.30.
- Liquidity remained substantial
- Cash and cash equivalents were $1,022.9 million at July 5, 2026. The debt portfolio was primarily fixed-rate, and no interest-rate derivative instruments were outstanding at quarter-end.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- China divestiture execution risk
- The company agreed to divest its China Immunodiagnostics business, which represented approximately 6% of fiscal 2025 revenue and is expected to close by the end of 2027. Failure to execute the divestiture could result in unexpected transaction costs and operational disruption.
- Large intangible asset impairment exposure
- Net intangible assets totaled $8.8 billion at July 5, 2026. Adverse business changes or failure to grow the Life Sciences and Diagnostics segments could trigger impairment charges and pressure earnings.
- Dividend may be reduced or eliminated
- The company declared quarterly dividends of $0.07 per share for both Q2 and Q3 2026, but stated that the Board may reduce or eliminate the dividend to fund growth, repurchase shares, or conserve capital.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.41
- Segment
- Diagnostics: 11% organic growth, according to management's Q2 earnings commentary.
- Segment
- Life Sciences: organic revenue declined; the filing extract does not provide a segment revenue amount or decline percentage.
What they said about what is next.
Full-year 2026 pro forma guidance excludes the China Immunodiagnostics business. Revenue guidance was raised from $2.81-$2.84 billion to $2.83-$2.86 billion, and adjusted EPS guidance from $5.20-$5.30 to $5.30-$5.40. Pro forma organic revenue growth outlook is 4%-5%.
The filing reads better than the one before it.
What came before.
- 10-Q · May 12, 2026
- Revvity, Inc. achieved strong Q1 2026 results with revenue of $711.1 million and EPS of $1.06, both better than analyst expectations. The company highlighted growth in both its Diagnostics and Life Sciences segments,…
- 10-K · February 24, 2026
- Revvity frames its strategy around expanding Life Sciences and Diagnostics offerings through R&D, AI and targeted acquisitions while maintaining disciplined capital allocation. Using quarterly results published in the…
- 10-Q · May 6, 2025
- Revvity reported Q1 revenue of $664,762 (in thousands), up $14,842 vs the year-ago quarter, with operating income rising to $72,230 (in thousands) from $44,116 and diluted EPS from continuing operations of $0.35 (vs…
- 10-Q · August 6, 2024
- Revvity reported Q2 revenue of $691,685,000 (down $17,381,000 vs prior-year quarter) with continuing operating income of $85,724,000 (up $7,668,000 YoY) and net income of $55,360,000 (up $19,801,000 YoY). Cash and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing RVTY makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever